Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Passage Bio ( (PASG) ) has shared an announcement.
Passage Bio announced a 1-for-20 reverse stock split of its common stock, effective July 14, 2025, to comply with Nasdaq’s minimum bid price requirement. This move, approved by stockholders and the Board, reduces the number of outstanding shares significantly, with no change to ownership percentages or authorized shares, and adjusts equity awards proportionately.
The most recent analyst rating on (PASG) stock is a Buy with a $2.00 price target. To see the full list of analyst forecasts on Passage Bio stock, see the PASG Stock Forecast page.
Spark’s Take on PASG Stock
According to Spark, TipRanks’ AI Analyst, PASG is a Neutral.
Passage Bio scores moderately low due to its financial challenges, including no revenue and significant cash burn. However, a strong balance sheet and recent corporate event announcements, including program advancements and extended cash runway, provide some optimism. Technical indicators suggest a neutral to bearish sentiment, and traditional valuation metrics are limited due to the company’s stage and lack of profitability.
To see Spark’s full report on PASG stock, click here.
More about Passage Bio
Passage Bio, Inc. is a clinical-stage genetic medicines company focused on developing therapies for neurodegenerative diseases. Its lead product candidate, PBFT02, aims to treat conditions like frontotemporal dementia by elevating progranulin levels to restore lysosomal function and slow disease progression.
Average Trading Volume: 372,074
Technical Sentiment Signal: Sell
Current Market Cap: $24.92M
For detailed information about PASG stock, go to TipRanks’ Stock Analysis page.